Expertise in
5
conditions

Ling J. Li

No.1 Jianshe East Road, 
Zhengzhou, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
No.1 Jianshe East Road, 
Zhengzhou, CN 
OverviewLocationsClinical Research

Overview

Ling Li practices in Zhengzhou, China. Ms. Li is highly rated in 5 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and T-Cell Lymphoma.

Her clinical research consists of co-authoring 119 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

No.1 Jianshe East Road, Zhengzhou, 450052, China
Other Locations
No.1 Jian She Road, Zhengzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Enrollment Status: Recruiting
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: rhNRG-1
Study Phase: Phase 3
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Enrollment Status: Terminated
Publish Date: December 21, 2017
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trial

119 Total Publications

Multi-scenario Land Cover Simulation and Carbon Stock Assessment in Shaanxi Province Based on the PLUS-InVEST Model
Multi-scenario Land Cover Simulation and Carbon Stock Assessment in Shaanxi Province Based on the PLUS-InVEST Model
Journal: Huan jing ke xue= Huanjing kexue
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Li's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile